Stock market announcement archive

April 25, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. Reference is made to the stock exchange announcement published […]
Read more
April 25, 2024
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF […]
Read more
April 9, 2024
Bergen, Norway, April 9th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Annual Report 2023. – The technology development and company progress were fantastic in 2023. We expect nothing less in 2024, in our mission to make life easier for patients […]
Read more
April 3, 2024
Bergen, Norway, 3rd April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully reached the target for pilot production of the Sencell sensor. Reports show a breakthrough, and this will pave the way for the automated production by end of Q2 as scheduled. Reference […]
Read more
March 21, 2024
Bergen, Norway, March 21st, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has notified that they will grant for a new patent to Lifecare. Reference is made to stock exchange notification November 8th, 2023, that EPO intended […]
Read more
March 5, 2024
Bergen, Norway, 5 March 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a cleanroom. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th, 2023 and later […]
Read more
February 27, 2024
Bergen, Norway, February 27th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q4 financial report and operational update. Lifecare holds steady a course towards the upcoming automated pilot production. The first three quarters of 2023, Lifecare reported on huge achievements both […]
Read more
February 21, 2024
Bergen, Norway, February 21st, 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces today that the Board of Directors has decided to prepare for submitting application for listing of Lifecare’s shares at the main list of Oslo Stock Exchange (OSE), transferring from the current listing […]
Read more
January 23, 2024
Bergen, Norway, 23 January 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has appointed Renete Kaarvik as Chief Financial Officer effective 1 Mai, 2024. Kaarvik joins Lifecare from the position as Global Finance Officer at Grieg Seafood ASA, a position she has held for close […]
Read more
January 9, 2024
Bergen, Norway, January 9th, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has received the official documentation for ISO 13485 certification. Reference is made to Lifecare’s stock exchange notification 27th of November 2022 when the ISO 13495 […]
Read more